FATE THERAPEUTICS INC

FATE

FATE THERAPEUTICS INC

FATE

Insider Sentiment (TTM):

Last Purchase:2024-12-20Last Sale:2026-05-20Shares Purchased (TTM):0Shares Sold (TTM):70,315

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:69,310,911Shares Outstanding:120,030,638Institutional Ownership Pct.:57.74%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	32	40	47	41	41	45	36	38	37	121	42	33
Accounts Receivable Net Current	1	1	1	1	1	2	4	4	1	1	2	2
Short Term Investments	121	135	157	175	182	196	243	259	268	-	273	-
Prepaid Expense And Other Assets Current	3	4	4	5	6	5	9	9	13	10	15	13
Assets Current	158	180	209	221	230	248	292	310	319	394	332	364
Long Term Investments	0	0	1	10	26	32	28	34	47	8	1	0
Property Plant And Equipment Net	52	54	57	59	61	63	64	82	88	92	97	102
Operating Lease Right Of Use Asset	41	41	42	42	44	45	47	58	60	61	62	63
Restricted Cash Noncurrent	10	10	10	10	10	10	10	10	15	15	15	15
Other Assets Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Contract With Customer Asset Net Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Assets	260	285	319	344	372	399	441	495	529	570	506	544
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	3	3	4	4	4	9	6	5	7	5	6
Accrued Liabilities Current	15	14	20	18	18	17	21	24	23	32	28	29
Contract With Customer Liability Current	0	1	0	0	0	0	0	1	0	0	1	1
Operating Lease Liability Current	5	5	5	5	6	7	7	7	7	6	6	6
Liabilities Current	33	31	36	28	29	28	39	37	35	45	39	41
Operating Lease Liability Noncurrent	71	72	73	74	76	77	78	92	94	96	97	99
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,749	1,745	1,741	1,736	1,731	1,724	1,716	1,707	1,695	1,686	1,580	1,571
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	1	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-1,596	-1,566	-1,534	-1,502	-1,470	-1,436	-1,398	-1,346	-1,298	-1,260	-1,212	-1,168
Stockholders Equity	153	180	207	234	261	288	319	362	397	426	368	403
Liabilities And Stockholders Equity	260	285	319	344	372	399	441	495	529	570	506	544
Convertible Preferred Stock	-	3	3	0	0	3	3	0	0	3	3	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	3	-	-	-
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	3	-	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	350	350	350	350	350	250	2,500	250	250	250	250	250
Common Stock Shares Issued	117	116	115	115	115	115	114	114	114	114	99	99
Shares Outstanding	117	116	115	115	115	115	114	114	114	114	99	99

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.48%	36.45%	14.49%	-	-	-	-	-	-	-	-	-
2025	60.00%	12.00%	7.00%	7.45%	28.72%	43.62%	9.09%	0.00%	20.20%	-29.49%	-10.90%	12.82%
2024	-5.64%	-15.90%	39.49%	1.50%	-3.59%	-27.25%	11.34%	-24.37%	-45.38%	-6.59%	40.66%	27.47%
2023	-	-	-	-	-	-	13.73%	60.52%	95.71%	-4.89%	-31.08%	-43.88%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.85	5.85	5.79	7.87	8.04	8.81	7.58	8.29	9.18	8.69	8.48	8.81
Quick Ratio	4.74	5.72	5.67	7.69	7.82	8.62	7.34	8.04	8.79	8.47	8.11	8.50
Working Capital	125.36M	148.84M	172.63M	193.14M	201.72M	220.06M	253.39M	272.87M	284.60M	349.01M	292.45M	322.84M
Leverage & Debt
Debt to Equity	0.21	0.17	0.17	0.12	0.11	0.10	0.12	0.10	0.09	0.11	0.11	0.10
Debt Ratio	0.13	0.11	0.11	0.08	0.08	0.07	0.09	0.08	0.07	0.08	0.08	0.08
Efficiency & Turnover
Asset Turnover TTM	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.03	0.02	0.01	0.10	0.16
Days Sales Outstanding TTM	58.99	89.86	122.33	122.97	52.64	44.67	71.83	76.88	57.50	404.50	115.78	20.21
Receivables Turnover TTM	6.19	4.06	2.98	2.97	6.93	8.17	5.08	4.75	6.35	0.90	3.15	18.06
Per Share Metrics
Diluted EPS TTM	-1.05	-1.08	-1.15	-1.31	-1.45	-1.49	-1.64	-1.51	-1.50	-1.88	-1.64	-1.76
Free Cash Flow Per Share TTM	-0.88	-0.90	-0.94	-0.97	-1.00	-1.06	-1.09	-1.13	-1.20	-1.38	-1.41	-1.86
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-2,058.08%	-2,207.47%	-2,222.45%	-2,448.24%	-2,271.23%	-1,503.47%	-1,542.63%	-1,462.06%	-1,587.28%	-3,287.85%	-299.86%	-194.75%
Net Profit Margin TTM	-1,941.09%	-2,056.79%	-2,051.08%	-2,187.11%	-2,025.05%	-1,318.93%	-1,366.46%	-1,325.43%	-1,426.67%	-2,933.79%	-253.30%	-163.04%
Growth Metrics
Net Revenue Growth (1Y)	-23.36%	-52.64%	-51.24%	-46.92%	-31.23%	105.85%	-78.55%	-87.34%	-89.67%	-95.27%	-34.03%	53.91%
Net Income Growth (1Y)	-26.54%	-26.14%	-26.82%	-12.42%	-2.39%	-7.46%	15.74%	2.92%	-16.94%	-19.10%	-42.88%	-41.09%
EPS Growth (1Y)	-27.68%	-27.16%	-29.96%	-13.33%	-3.26%	-20.96%	0.19%	-13.86%	-30.42%	-21.54%	-43.80%	-42.02%
Valuation Metrics
P/E TTM	-2.58	-1.11	-0.85	-0.96	-0.77	-0.53	-1.01	-2.31	-2.19	-3.90	-2.29	-1.21
P/B TTM	2.12	0.80	0.56	0.64	0.51	0.32	0.59	1.14	0.97	1.74	1.00	0.52
P/S TTM	50.08	22.81	17.52	21.01	15.67	7.01	13.76	30.65	31.28	114.56	5.79	1.97
Market Cap	325.07M	144.04M	116.41M	149.94M	132.75M	93.52M	187.58M	412.19M	385.30M	742.11M	368.06M	208.96M
Enterprise Value	292.64M	104.47M	69.79M	109.32M	91.50M	48.60M	151.52M	374.28M	348.38M	620.78M	326.19M	175.63M
Calculated Values
Free Cash Flow TTM	-105.62M	-108.09M	-112.04M	-115.43M	-118.77M	-125.17M	-123.60M	-132.53M	-141.45M	-139.78M	-138.42M	-183.66M
Net Debt	-32.43M	-39.57M	-46.63M	-40.62M	-41.25M	-44.92M	-36.06M	-37.91M	-36.92M	-121.32M	-41.87M	-33.33M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-20Sale

Owner: Valamehr, Bahram

Title: President and CEO

Shares: 28,946

Price/Share: $1.88

Value: $54,418.48

Shares Owned: 635,762

Relationship: Director,Officer

Ownership: Direct

2026-05-20Sale

Owner: Tahl, Cindy

Title: See Remarks

Shares: 25,590

Price/Share: $1.88

Value: $48,109.20

Shares Owned: 628,155

Relationship: Officer

Ownership: Direct

2026-01-09Sale

Owner: Tahl, Cindy

Title: See Remarks

Shares: 10,589

Price/Share: $1.06

Value: $11,224.34

Shares Owned: 387,081

Relationship: Officer

Ownership: Direct

2026-01-09Sale

Owner: Valamehr, Bahram

Title: President and CEO

Shares: 5,190

Price/Share: $1.07

Value: $5,553.30

Shares Owned: 329,708

Relationship: Director,Officer

Ownership: Direct

2025-08-04Sale

Owner: Tahl, Cindy

Title: See Remarks

Shares: 9,037

Price/Share: $1.06

Value: $9,579.22

Shares Owned: 397,670

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-20	Valamehr, Bahram	Director,Officer	President and CEO	Direct	Sale	28,946	1.88	$54,418.48	635,762	4
2026-05-20	Tahl, Cindy	Officer	See Remarks	Direct	Sale	25,590	1.88	$48,109.20	628,155	4
2026-01-09	Tahl, Cindy	Officer	See Remarks	Direct	Sale	10,589	1.06	$11,224.34	387,081	4
2026-01-09	Valamehr, Bahram	Director,Officer	President and CEO	Direct	Sale	5,190	1.07	$5,553.30	329,708	4
2025-08-04	Tahl, Cindy	Officer	See Remarks	Direct	Sale	9,037	1.06	$9,579.22	397,670	4
2025-08-04	Valamehr, Bahram	Director,Officer	President and CEO	Direct	Sale	14,466	1.06	$15,333.96	334,898	4
2025-01-10	Tahl, Cindy	Officer	See Remarks	Direct	Sale	5,654	1.55	$8,763.70	336,707	4
2025-01-10	Bressi, Jerome Charles	Officer	See Remarks	Direct	Sale	5,980	1.55	$9,269.00	270,203	4
2025-01-10	Valamehr, Bahram	Director,Officer	President and CEO	Direct	Sale	8,705	1.54	$13,405.70	349,364	4
2024-12-20	Green, Jeremy, Redmile Gr…	Director,TenPercentOwner	-	Indirect	Purchase	397,964	1.68	$668,579.52	12,884,277	4
2024-12-20	Green, Jeremy, Redmile Gr…	Director,TenPercentOwner	-	Indirect	Sale	341,633	1.68	$573,943.44	12,486,313	4
2024-08-06	Xu, Yuan	Director	-	Direct	Sale	633	4.23	$2,677.59	8,669	4
2024-03-04	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	2,447	7.77	$19,013.19	101,479	4
2024-01-29	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	1,849	5.00	$9,245.00	103,926	4
2024-01-09	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	7,028	4.37	$30,712.36	105,775	4
2024-01-09	Tahl, Cindy	Officer	General Counsel and Secretary	Direct	Sale	10,874	4.37	$47,519.38	142,361	4
2024-01-09	Wolchko, J Scott	Director,Officer	President and CEO	Direct	Sale	14,391	4.37	$62,888.67	371,248	4
2024-01-09	Valamehr, Bahram	Officer	Chief R&D Officer	Direct	Sale	11,271	4.38	$49,366.98	158,069	4
2024-01-02	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	5,182	3.66	$18,966.12	112,803	4
2023-12-26	Redmile, Group, Llc, Gree…	Director,TenPercentOwner	-	Indirect	Purchase	44,630	3.72	$166,023.60	13,180,388	4
2023-12-18	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	1,585	3.50	$5,547.50	117,985	4
2023-11-09	Tahl, Cindy	Officer	General Counsel and Secretary	Direct	Sale	24,363	2.40	$58,471.20	153,235	4
2023-08-18	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	4,718	2.80	$13,210.40	119,570	4
2023-08-04	Xu, Yuan	Director	-	Direct	Sale	632	3.71	$2,344.72	9,302	4
2023-07-05	Powl, Brian T.	Officer	Chief Commercial Officer	Direct	Sale	3,854	4.87	$18,768.98	41,146	4
2023-07-05	Dulac, Edward J Iii	Officer	Chief Financial Officer	Direct	Sale	5,182	4.83	$25,029.06	124,288	4
2023-06-14	Xu, Yuan	Director	-	Direct	Sale	3,460	5.58	$19,306.80	9,934	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

57.74%

Inst. Shares: 69,310,911

Shares Outstanding: 120,030,638

2025-12-31

57.61%

Inst. Shares: 68,434,687

Shares Outstanding: 118,789,974

2025-09-30

64.79%

Inst. Shares: 77,101,523

Shares Outstanding: 118,998,693

2025-06-30

64.11%

Inst. Shares: 75,994,028

Shares Outstanding: 118,528,046

2025-03-31

78.78%

Inst. Shares: 93,256,649

Shares Outstanding: 118,375,540

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	69,310,911	120,030,638	57.74%
2025-12-31	68,434,687	118,789,974	57.61%
2025-09-30	77,101,523	118,998,693	64.79%
2025-06-30	75,994,028	118,528,046	64.11%
2025-03-31	93,256,649	118,375,540	78.78%
2024-12-31	98,525,374	113,685,177	86.67%
2024-09-30	111,839,810	117,769,161	94.97%
2024-06-30	119,256,950	117,468,124	101.52%
2024-03-31	120,445,690	101,104,345	119.13%
2023-12-31	91,795,806	98,411,162	93.28%
2023-09-30	90,769,745	98,568,012	92.09%
2023-06-30	103,815,291	98,400,355	105.50%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

FATE THERAPEUTICS INC (FATE) — SEC Financial Statements & Analysis

FATE THERAPEUTICS INC (FATE) is a biological products, (no diagnostic substances) company. FATE THERAPEUTICS INC trades on Nasdaq as: FATE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), FATE THERAPEUTICS INC reported a -23.36% year-over-year revenue growth, a Debt-to-Equity ratio of 0.21x, a Price-to-Sales (P/S) ratio of 50.08x (TTM), a Price-to-Book (P/B) ratio of 2.12x (TTM), at a market cap of $325.07M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -23.36%
Debt To Equity: 0.21x
P/S TTM: 50.08x
P/B TTM: 2.12x
Market Cap: $325.07M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is FATE THERAPEUTICS INC in?

FATE THERAPEUTICS INC (FATE) operates in the Biological Products, (No Diagnostic Substances) industry.

What is FATE's market cap?

FATE THERAPEUTICS INC (FATE) has a market capitalization of $325.07M as of 2026-06-30.

What exchange does FATE trade on?

FATE THERAPEUTICS INC (FATE) trades on the Nasdaq.